We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Abbott Diagnostics Displays Alinity Family of Systems

By LabMedica International staff writers
Posted on 02 Aug 2018
Abbott Diagnostics (Abbott Park, IL, USA) displayed the Alinity next-generation family of systems at this year’s AACC Annual Scientific Meeting & Clinical Lab Expo in Chicago, Illinois, USA. More...
The Alinity harmonized family of systems across key laboratory disciplines is designed to simplify diagnostics and help deliver results that drive better patient outcomes.

Abbott's Alinity family of harmonized solutions is unprecedented in the diagnostics industry, working together to address the challenges of using multiple diagnostics platforms and simplify diagnostic testing. Alinity systems are designed to be more efficient – running more tests in less space, generating test results faster and minimizing human errors – while continuing to provide quality results.

The Alinity portfolio includes clinical chemistry, immunoassay, blood and plasma screening, point of care, hematology and molecular diagnostics, along with Abbott's AlinIQ—a first-of-its-kind, holistic suite of professional services that combines expertise with process analysis and informatics.

The Alinity ci-series combines the power of integrated clinical chemistry and immunoassay systems in unprecedented, innovative combinations to meet every laboratory's needs. The Alinity h-series solution integrates the Alinity hq with the Alinity hs slide maker and stainer module into a combined solution for hematology testing. The Alinity h-series solution is 20% faster per m2 than other currently available integrated hematology systems with a throughput of 133 complete blood counts (CBCs) per m2.

The Alinity m molecular system addresses operational complexities, such as increasing the capacity for growth, improving workflow efficiencies and reducing demand on labor. The Alinity s system for blood and plasma screening is designed to screen blood and plasma faster and more efficiently within a smaller footprint, helps blood and plasma centers improve productivity and maintain the highest levels of accuracy, without expanding the instrument footprint.

The Alinity PRO software works with all Alinity systems to fully maximize their potential and enhance operational productivity throughout the network, allowing for easier and consolidated system monitoring anytime, anywhere. And with predictive system monitoring through AlinIQ Always On, Abbott’s professional services can proactively monitor the health of these systems and help avoid unexpected downtime.


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
Amoebiasis Test
ELI.H.A Amoeba
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.